Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study.

Chen L., Trukhin D., Kolesnik O., David Gomez Rangel J. D., Cil T., Li X., ...Daha Fazla

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, cilt.40, (Özet Bildiri) identifier

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 40
  • Basıldığı Ülke: ELECTR NETWORK
  • Trakya Üniversitesi Adresli: Evet